EGFR and non-small cell lung carcinoma: Within the landscape of NSCLC tumors, EGFR mutations emerge as prominent drivers, with the exon 21 Leu858Arg (21L858R) mutation and the exon 19 deletion (19del) standing out as the two most prevalent and clinically significant subtypes [3–5].